Home
This site is intended for healthcare professionals

Global OSA Institute Insights Podcast: Episode 3 Closing the Access Gap in OSA

Share

Description

This program is supported by an independent educational grant from Lilly.

Join Dr. Douglas Kirsch for this CME-accredited podcast as he explores how clinicians can help close the access gap in obstructive sleep apnea (OSA) by streamlining diagnosis and treatment without compromising patient safety.

Using a real-world patient case, this episode examines practical approaches to identifying bottlenecks, using HSAT appropriately, triaging patients who need specialist assessment, and starting treatment promptly. It also explores how integrated obesity and cardiometabolic care can help create more connected and equitable OSA pathways.

This is episode Three of Three, find episodes One and Two here.

Who Should Listen?

Primary care physicians and sleep specialists involved in the care of patients with OSA.

This podcast has four segments:

  • Uncover the barriers that can delay OSA diagnosis and treatment.
  • Explore smarter diagnostic pathways to help the right patients reach testing sooner.
  • Discover how to start treatment sooner without compromising support or patient choice.
  • Connect the dots across care by integrating OSA, obesity, and cardiometabolic management.

Faculty

Dr Douglas Kirsch is Medical Director of Sleep Medicine at Atrium Health and a Professor of Internal Medicine and Neurology. A board-certified sleep medicine specialist, he has extensive expertise in the diagnosis and management of sleep disorders, with a particular research focus on obstructive sleep apnea. His research examines the impact of OSA treatment on patient hospitalizations and explores the use of consumer wearable devices to assess sleep in the home setting. Dr Kirsch is a former President of the American Academy of Sleep Medicine and is dedicated to improving sleep health and patient well-being.

Disclosures

Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are mitigated according to Partners policies.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.

Dr Douglas Kirsch, faculty for this educational activity, has the following relevant financial relationships: Scientific Advisory Board Apnimed, Incannex, Huxley Medical. Expert Panel Carelon. Consulting ResMed.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and MedAll. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Education

Partners designates this live activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Associate Continuing Education

Partners has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.5 ANCC contact hours.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Fee Information

There is no fee for this educational activity.

This continuing education activity is active starting October 6th 2026, and will expire on July 1st 2028.

Learning objectives

By the end of this Program Learners should be better able to:

Integrate OSA diagnosis into cardiometabolic risk assessment and management through screening of high-risk patients and coordinated cardiometabolic care.

Implement evidence-based, multimodal OSA treatment plans that integrate PAP therapy, cardiometabolic management, and emerging pharmacotherapy, applying a multidisciplinary, chronic-disease model.

Implement simplified, accessible diagnostic algorithms and integrated obesity-CVD-OSA care pathways to overcome diagnostic bottlenecks, reduce care fragmentation, and improve timely access to evidence-based treatment for patients with moderate-to-severe OSA across diverse healthcare settings.

Similar communities

View all

Similar events and on demand videos

Computer generated transcript

Warning!
The following transcript was generated automatically from the content and has not been checked or corrected manually.

Hello and welcome to Global OSA Institute Insights. This episode is titled Closing the Access Gap in OSA. This independent accredited educational activity is intended for primary care physicians and sleep specialists who care for adults with obstructive sleep apnea. It is supported by an independent educational Grant from Lily. Today, we are joined by Doctor Douglas Kirsch, medical director of sleep medicine for Atrium Health and professor at the Wake Forest School of Medicine. Today, we will focus on how a mixed access system in the US can shorten the route from high clinical suspicion to diagnosis and treatment without compromising safety. Let's start with a case again. A 54-year-old man has obesity, resistant hypertension, and type 2 diabetes. BMI is 37 kg per square meter. BP is 156.94 of a millimeter of mercury. HbA1c is 8.2%, 66 millimoles per mole. He reports loud snoring, witnessed apnea. morning headaches, and daytime sleepiness. ESS is 14. Clinical suspicion of moderate to severe OSA is high, but the wait for in laboratory polysomnography is several months. No HSAT pathway or sleep specialist triage has been initiated. Obesity, cardiovascular risk, and suspected OSA are being managed separately. Decision point. How can the system shorten the path safely for this uncomplicated high-risk patient while protecting complex patients who still need laboratory testing? I am going to turn to Doctor Kirsch. Where is the true bottleneck in this case? Recognition, testing capacity, referral design, payer rules, or failure to assign responsibility? And how should a service map it? So care of patients can sometimes be tricky. So, in this particular case, there is a lot of places where uh this patient can fall through the cracks. And so, where is the first problem, I think it's a recognition that this patient has been referred potentially for uh in-lab polysomnogram, but the wait time is really long for that in this particular patient's patient's uh location. So the first thing to recognize is, OK, the good news is somebody has already recognized that sleep apnea is a problem. Um, let's find out how we can manage that faster. Home testing generally has a much less or much lower wait time than in laboratory polysomnogram. In our practice, um, it's a matter of 2 or 3 weeks for home testing versus sometimes 1 month to 2 months for laboratory testing. Um, and this may vary from location to location, but The key is that there is another choice for this particular patient, which is, OK, you know, could this patient get referred for a home test and would that speed up the care of this particular patient who has multiple issues, as you can see, both from a perspective of obesity, hypertension, and diabetes. So One option in this case would be to refer directly to the sleep doctor, uh, and see if they can get the patient in and managed more quickly. A second would be to send them directly for home testing. This may vary based on your practice location, but it's important to recognize that there are choices for this patient that doesn't necessarily always involve having to wait a long period of time, um, to get in in laboratory test. So, uh, to close the loop here, um, recognize that finding a pathway that will speed the care of this patient is important. Whether that's referral to a sleep clinician, whether that's a direct referral to a home test may vary based on your practice, but it's important not to let this particular problem drop. That treatment of this patient's sleep apnea may help with their BP, may help with their diabetes, um, and Uh, and may help them feel less sleepy, as you can see with their F4 14. So, Try and get this patient better care, whether that be direct. For that patient to get a test or to see a sleep clinician. For an uncomplicated patient with high probability of moderate to severe OSA, what is the minimum safe HSAT first algorithm? So, I, I will say as a practicing sleep physician, um, I view that it is always helpful for me to be involved in the care of sleep patients, but I also recognize that sleep practices are a limited resource in many areas of the country. And so it's important to recognize that there aren't enough sleep doctors to manage all of the sleep apnea patients who are out there. So, how might you look at a pathway? The pathway would include a recognition of the patient. So whether that's with a questionnaire or targeted questions about possible sleep apnea done in primary care practice. Second, if possible, a referral to a home test can occur. That pathway has to include a sleep doctor interpreting that home test. That's the only way that home tests. are validated to occur and all sleep tests need a sleep doctor to review them. Third, if at that point a positive result is obtained, either A, that patient could then be referred to sleep care to manage that patient, or that patient can meet with their referring clinician to review the results of the test and determine a pathway to treatment. In this patient, if the test was negative, I would still refer that patient to a sleep practice or arrange for it in laboratory test. A normal home test in Uh, a patient with this level of high risk should make people question whether that test was adequate because their risk is quite high. And so either repeat test at home or a laboratory test would be a reasonable decision at that point. And then in the end, just because the test has been done, it's important that there be a closed loop and that that patient returns for follow-up either in sleep or in primary care to review the results of that test and determine what appropriate next step is occurred. How should the pathway safely manage patients who are not suitable for routine HSAT but face a long wait for in laboratory testing? So this is tricky, um, that certainly patients who are sick, um, who patients who have, uh, hypoventilation or major cardiopulmonary disease or Heart failure or neuromuscular weakness or other, some other form of hypoxemia. All these patients um are probably not appropriate for a home test. We think again, just as a reminder that home testing is best. Um, occurs in patients who have a moderate to high pretest probability of sleep apnea with a relatively uncomplicated medical history. So in this particular case, a home test might not be appropriate for a patient who is quite ill. But a test in a laboratory can take a long time. And it's important then to try and push this along a little bit. And sometimes that can be as simple as, hey, I have a very sick patient who needs care sooner rather than later. And in that case, Trying to talk to the sleep practice that is managing that laboratory to see if there's anything that can be done to move that patient. To a faster process. Now, is there anything else that can be done? Well, while you're waiting, you can still be working on the other things, and in this case, whether that be the diabetes, the hypertension, and the weight, right? Each of those pieces can be worked on simultaneously while waiting for in laboratory testing. Also, it's worth thinking about whether there may be a referral that is more convenient, but a longer wait versus a perhaps slightly longer drive for that patient to another center that might have a shorter wait. Again, important to recognize what's available in your community and say, hey, if this is not a good choice, is there another choice that's out there? It is important to recognize that doing a home test in an inappropriate patient does not usually give you a great result and can complicate things for that patient. So, in a patient, for instance, who has severe hypoxemia, doing a home test um is going to make it very difficult to understand, um. What that result might be. And it might be negative um for sleep apnea, but only because the oxygen was so low. Or if a patient is on supplemental oxygen, doing a home test is not a great idea because you are not going to pick up on the things that are gonna let you see sleep apnea. Doing a bad, doing the wrong test, even if faster, isn't gonna give you necessarily a better result. So, To close the loop here, treat the patient.